Kisspeptin-10

5mg Vial

10mg Vial

2 September 2026Updated 2 September 2026

Kisspeptin-10

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Kisspeptin-10.

Create free account Member login

Full range of benefits for Kisspeptin-10

Stimulates GnRH release via KISS1R, increasing LH and FSH secretion

Can provoke an LH surge for diagnostic testing of HPG axis function

Investigational agent to induce ovulation in assisted reproduction

May help evaluate hypothalamic causes of delayed puberty or hypogonadism

Circulating kisspeptin may reflect placental function and pregnancy status

Research tool to study GnRH neuron activity and hormone pulsatility

Preclinical studies show anti‑metastatic effects in some cancer models

Research suggests modulation of sexual behavior and libido in models

May enable ovulation induction strategies with lower OHSS risk in studies

Can help differentiate functional hypothalamic amenorrhea from ovarian failure

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 13 known interactions

Synergistic(3)Compatible(3)Monitor(3)Avoid(4)

Generally well-tolerated alongside this peptide

Metformin

Metformin used in insulin-resistant PCOS has no direct pharmacokinetic interaction with kisspeptin and is generally neutral when co-administered, although reproductive outcomes should be clinically assessed.

Levothyroxine

Thyroid hormone replacement does not have a known direct interaction with kisspeptin administration and can be continued with routine thyroid function monitoring.

Selective serotonin reuptake inhibitors (SSRIs)

SSRIs have no established pharmacodynamic or pharmacokinetic interaction with kisspeptin, though clinicians should be aware of potential effects of SSRIs on sexual function separate from reproductive hormone monitoring.

All interaction categories

Synergistic (3)

Human chorionic gonadotropin (hCG): hCG given as a luteal or ovulation trigger can act downstream of kisspeptin-induced LH surge to support final oocyte maturation and luteal function, producing an additive effect in assisted reproduction protocols.
Recombinant gonadotropins (rFSH/rLH, hMG): Exogenous gonadotropins used for controlled ovarian stimulation complement kisspeptin's ability to induce endogenous LH/FSH release, enhancing follicular growth and maturation when used together.
Pulsatile gonadotropin-releasing hormone (GnRH) therapy: Pulsatile GnRH and kisspeptin both stimulate the hypothalamic–pituitary–gonadal axis and can have additive effects on restoring gonadotropin secretion in hypothalamic amenorrhea or infertility settings.

Compatible (3)

Metformin: Metformin used in insulin-resistant PCOS has no direct pharmacokinetic interaction with kisspeptin and is generally neutral when co-administered, although reproductive outcomes should be clinically assessed.
Levothyroxine: Thyroid hormone replacement does not have a known direct interaction with kisspeptin administration and can be continued with routine thyroid function monitoring.
Selective serotonin reuptake inhibitors (SSRIs): SSRIs have no established pharmacodynamic or pharmacokinetic interaction with kisspeptin, though clinicians should be aware of potential effects of SSRIs on sexual function separate from reproductive hormone monitoring.

Monitor (3)

Antipsychotics that elevate prolactin (e.g., risperidone, paliperidone): Drugs that raise prolactin can blunt kisspeptin-mediated GnRH/LH responses, so prolactin levels and LH/FSH response should be monitored and adjusted if blunted efficacy is suspected.
Exogenous sex steroids (estrogen/progestin therapy, including combined oral contraceptives): Sex steroid therapy alters hypothalamic feedback and can attenuate kisspeptin responsiveness, requiring monitoring of gonadotropins and estradiol and possible adjustment of timing or dosing.
Controlled ovarian stimulation regimens (monitoring of estradiol and follicle development): When kisspeptin is used in assisted reproduction alongside gonadotropins, serum estradiol and transvaginal follicle monitoring are required to assess ovarian response and OHSS risk.

Avoid (4)

Pregnancy and breastfeeding: Kisspeptin safety in pregnancy and lactation is not well established and use should be avoided or carefully justified due to potential effects on placental and fetal endocrine function.
Hormone-sensitive malignancies (e.g., estrogen receptor–positive breast or endometrial cancer): Because kisspeptin stimulates gonadotropin release and can increase downstream sex steroid production, use should be carefully evaluated in patients with hormone-sensitive tumors.
Polycystic ovary syndrome (PCOS) with high ovarian reserve: Although kisspeptin may reduce OHSS risk compared with hCG, patients with PCOS and high ovarian reserve remain at elevated risk for excessive response and should be assessed cautiously.
Uncontrolled pituitary disease (macroadenomas, hypopituitarism): Underlying pituitary pathology can unpredictably alter response to kisspeptin and may exacerbate mass effect or hormone imbalances, warranting specialist endocrine evaluation prior to use.